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Implications of Pharmacokinetic Modeling
in Risk Assessment Analysis
by Robert J. Lutz* and Robert L. Dedrick*
Physiologic pharmacokinetic models are auseful interface between exposuremodelsand riskassessment
models by providing a means to estimate tissue concentrations of reactive chemical species at the site of
action. The models utilize numerous parameters that can be characterized as anatomical, such as body
size or tissue volume; physiological, such as tissue blood perfusion rates, clearances, and metabolism;
thermodynamic, such as partition coefficients; and transport, such as membrane permeabilities. The
models provide a format to investigate how these parameters can influence the disposition of chemicals
throughout the body, which is an important consideration in interpreting toxicity studies. Physiologic
models can take into account nonlinear effects related to clearance, metabolism, or transport. They allow
for extrapolation of tissue concentration from high dose to low dose experiments and from species to
species and can account for temporal variations in dose.
Introduction
The ever-increasing distribution of anthropogenic
chemicals into our environment requires more sophis-
ticated methods for estimating the risks posed to pop-
ulations exposed to these chemicals. On one hand, pro-
cedures are being developed for determining the mag-
nitude ofambient exposure levels and body burdens of
these materials, while on the other hand, mathematical
models are being derived to calculate estimates of the
risks ofcancer ordeath aftersuch exposure. The former
analysis involves exposure models, and the latter analy-
sis refers to risk assessment models. This paper de-
scribes the concepts of a pharmacokinetic model and
illustrates how such models can be a beneficial interface
between the exposure models and the risk assessment
models to improve and make more reliable quantitative
estimates of risk. The fundamental concepts that form
the basis of pharmacokinetic models will be briefly de-
scribed in this paper, and a discussion of the various
parameters that these models require will be given.
Through the application ofpharmacokinetic models, in-
sight can be gained into the mechanisms by which phys-
iologic processes such as blood flow, membrane perme-
ability, binding, metabolism, etc., affect the response
of an organism after exposure to toxic agents by ex-
amining how these parameters influence the disposition
of the agents. Figure 1 depicts, schematically, the in-
terrelationship of the exposure, risk assessment, and
pharmacokinetic models. Risk assessment models are
designed to give some estimate of response after ex-
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posure to some dose. The environment is responsible
for providing the exposure or dose to the organ or or-
ganism that is represented by the pharmacokinetic
model. It is possible to circumvent the pharmacokinetic
model and derive relationships directly between re-
sponse and ambient exposure. However, recent re-
search activity in this area (1-3) has proposed a more
rational and fruitful approach that attempts to correlate
response of an organism with the tissue concentration
of a reactive chemical species such as a metabolite. As
a further step, some researchers propose a response
correlation with the concentration ofa particular intra-
cellular element at the site of action, such as DNA ad-
duct (4). In any event, the pharmacokinetic model lends
itself very readily to making estimates or predictions
of specific, local, effective concentrations or effective
doses, as labeled in Figure 1.
Biological Model
Figure 1 shows a hypothetical biological model in a
target organ within our pharmacokinetic model. The
biological model is further detailed in Figure 2 and rep-
resents a modified version of one proposed by Hoel et
al. (4), which follows from suggestions of Gehring and
Blau (1) andGillette (5). Chrepresentstheparentchem-
ical ofinterest, e.g., PCB, kepone, dioxin, etc., at some
concentration within the body resulting from exposure
byvariouspossibleroutes such asingestion, absorption,
or inhalation. RM is a reactive metabolic intermediate
that derives from Ch. CBG is a covalently bound, ge-
netically active species. For example, Anderson et al.
(3) propose that for vinyl chloride the CBG can be rep-
resentedby aDNAadductofavinylchloride metaboliteLUTZ AND DEDRICK
FIGURE 1. Interrelationship between exposure determination and risk assessment models using pharmacokinetic and biological models.
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FIGURE 2. Diagram of a simple biological model for the metabolic
fate of some carcinogens. [*] Indicates agenetically active species.
which represents initial genetic damage and eventually
can cause tumor growth (liver angiosarcomas). Cellular
processes may repair the altered material, for example,
by elimination ofaltered bases from DNA, yielding the
component labeled CBGR. This process is likely to be
enzymatic. The reactive metabolite may also interact
with nongenetic material in the cell such as protein,
represented by CBN. If CBG is not repaired, it may
cause heritable genetic transformation of a cell, which
through promotional stages can propagate into atumor.
The reactive metabolite, can be detoxified, for example
by the liver, and also cleared from the body. Not all of
these kinetic processes are linear. Some are enzymatic
and therefore follow more complex kinetics and are sat-
urable. The saturable kinetics proposed by this model
are shown in Figure 2.
In modifying the biological model as originally pro-
posed by Hoel (4), some additionalpharmacokinetic con-
cepts have been added that involve transport phenom-
ena as shown in Figure 2. These include blood flow by
the circulatory system, diffusionacrosscellmembranes,
and elimination mechanisms. These processes will be
discussed later to show their importance and relevance
to the proposed biological model and to the overall mat-
ter of risk assessment. Most toxicity studies, such as
bioassays, are done at reasonably high doses in order
to elicit an observable response (6), such as initiation of
a tumor or death in an experimental animal. However,
actual exposures ofinterest from an environmentalper-
spective usually occur at much lower doses. One objec-
tive of risk estimation is to extrapolate the high dose
experimentsto predictions ofriskatlowdoses, but such
extrapolations can be misleading if certain pharmacok-
inetic events are not taken into consideration. The pos-
sible consequences of the linear and nonlinear events
depicted in Figure 2 on the outcome of dose-response
prediction will be illustrated. We will assume, as sug-
gested by previous literature (4), that the response to
exposure can be directly correlated with the concentra-
tion of a reactive species, namely the CBG in Figure 2.
Figure 3 illustrates several interrelationships between
the applied dose andthe CBG concentration orresponse
for various kinetic or transport conditions.
Consider the simplest case in which all the transport
and kinetic mechanisms depicted in Figure 2 are linear.
The dose-response relationship for such a case is illus-
trated in Figure 3A, which shows that linearity is main-
tained at low and at high doses. Therefore, a linear
extrapolation of response data from the high dose re-
gion, where most data are actually collected, to the low
dose region would allow prediction of the low dose re-
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sponse. Suppose, however, that the repair or detoxifi-
cation steps ofthe biological model in Figure 2 were to
saturate at high applied doses. The CBG concentration
would increase rapidly with dose, as shown in the high
dose region in Figure 3B. Now, linear extrapolation
from a high dose experiment to zero dose would fall
above the actual low dose response curve, and would
overestimate the response at low doses. Conversely, if
the activation step or iftransport processes depicted in
Figure 2 were to saturate, then the concentration of
the CBG species would plateau as applied dose in-
creased, asshowninFigure3C, andlinearextrapolation
from a high dose experiment would underpredict actual
response at low doses. The important conclusion to
make from these figures is that some biochemical spe-
cies, such as a DNA adduct (CBG), are bettermeasures
of effective dose for extrapolation than administered
dose or exposure levels, and that it is within the realm
ofourphysiologic pharmacokinetic modelingtechniques
to be able to predict the effective concentration oftoxic
agentfromthe administered dosebytakingintoaccount
linear and nonlinearphysiological and anatomical mech-
anisms.
Pharmacokinetic Model
With this background in mind, a discussion of phys-
iologic pharmacokinetic models follows, with a few ex-
amples to illustrate how some pharmacokinetic events
are relevanttotoxicity. Pharmacokinetic modelsconsist
ofnumerous parameters such as blood flow, membrane
permeability, clearance, etc., which represent actual
physiological functions that influence the distribution
and disposition of chemicals in the body, thereby influ-
encing the concentration of CBG.
The mathematical bases ofthese models involve prin-
ciples that generally apply to any chemical agent in the
body, whether it is an anticancer drug for treatment or
a xenobiotic that causes toxicity. An example ofa phar-
macokinetic system is the model for PCB distribution
(7), shown schematically in Figure 4. The system is
composed of various compartments that are linked to-
gether by a flow network, namely the circulatory sys-
tem. The compartments represent regions of the body
such as discrete organs, e.g., liver or kidney, or they
may represent some widely distributed but physiolog-
ically similar tissue such as muscle or fat. Particular
compartments generally represent macroscopic re-
gions, but, ifwarranted, can also represent microscopic
regions such as a single capillary with surrounding tis-
sue. A compartment is included in a model if it repre-
sents a region of substantial uptake ofthe drug; ifit is
involved in a clearance process, such as excretion or
metabolism; or if it is a site of special interest due to
itstoxic response tothechemical, forexample, the bone
marrow or a tumor. Some compartments are termed
"lumped" compartments because the model assumes
that the concentration of a chemical in any portion of
the compartment is representative ofthe average con-
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FIGURE 4. Diagram of a pharmacokinetic model for polychlorinated
biphenyl in the mouse, rat, dog, and monkey.
centration inthe entire compartment, thatis, the chem-
icalis uniformly distributed throughout the region. Dis-
tributed models can also be formulated that take into
account concentration gradients in the tissue. Dose or
exposure may be initiated in the model in any com-
partment as an input term to that compartment. For
example, an IV injection is an input into the blood com-
partment, dermal absorption is an input to the skin
compartment, and oral or inhalation exposure could be
handled by including a stomach or lung compartment in
the model, respectively.
A single, lumped compartment can be further sub-
divided as shown in Figure 5. Here, the various trans-
port mechanisms are specifically illustrated. Blood or
plasma flow on the arterial side carries the chemical to
the capillary space of the compartment. Diffusion can
occur across capillary membranes into the interstitial
space, and finally transmembrane diffusion (transport)
can occur to the intracellular space, which is frequently
the ultimate site ofaction ofchemical toxicity. Efferent
blood leaves the compartment as the venous flow and
recirculates to the blood pool.
Mathematically, the modelconsists ofaseries ofmass
(material) balances on each chemical species around
each compartment. The material balances are in the
form of differential equations that take into account
blood flow, cell membrane permeability, binding, me-
tabolism, etc. These sets of equations are solved nu-
merically, and the resultant solutions represent simu-
lations of the concentration of parent chemical or me-
tabolites inallcompartments as afunctionoftime. Since
it has already been postulated that the concentration of
specific chemical components, such as a metabolite or a
DNA adduct at a specific site of action, is a more ap-
propriate correlate oftoxicity than administered dose,
a pharmacokinetic model becomes useful in estimating
these specific concentrations in any tissue over time.
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FIGURE 5. Detailed representation of a single compartment within an overall pharmacokinetic model as shown in Fig. 4.
The uses ofpharmacokinetic models are several fold:
They provide a means to extrapolate high dose exper-
imental studies to low dose predictions ofchemical con-
centration. They allow for interspecies extrapolation of
exposure experiments because the models are based on
physical-chemical principles that apply across species,
say, mouse to man, and they can be scaled from one
species to another by scaling the appropriate model pa-
rameters. Theyallowpredictions oftemporal variations
in tissue concentration that might occur after exposure
schedules that differ from routine bioassay studies.
Models cannot be perfect representations ofthe real
system, but represent approximations that give us a
didactic framework to gain insight into the various
mechanisms that control the time history of chemicals
in the body. This information may help us understand
the toxic responses of some agents.
The following examples show how pharmacokinetic
analysis is useful either in predicting or in interpreting
toxicity studies. These examples will be presented un-
der the heading ofthe category ofparameter that they
represent in the model.
Anatomical
Anatomical parameters relate primarily to size and
body structure, e.g., bodyweight, organ size, or tissue
space. Mammals have a remarkable geometric similar-
ity. Figure 4 illustrates the PCB model, which, from an
anatomical viewpoint, wasidentical formouse, rat, dog,
monkey, and man. Numerous anatomical features of
mammals have been correlated in the literature accord-
ing to body weight (8). To see how one anatomical pa-
rameter can influence chemical disposition in the body,
consider Figure 6. It presents a comparison of model
simulations and data for the distribution of
2,4,5,2',4',5'-hexachlorobiphenyl (HCB)inbloodandfat
ofthe rat (7). The initial model simulations were based
on compartments with constant volume. According to
the data, the half-life of HCB appears to be much
shorterthan the initial simulations. However, these ex-
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FIGURE 6. Data and model simulations for 2,4,5,2',4',5'-hexachlo-
robiphenyl distribution in blood and fat tissue in rat. Dotted line
represents simulation with constant rat size; solid line represents
simulation which takes into account a growing rat.
periments were conducted on young, growing rats,
which, overthe course ofthe experiment, were increas-
ing both in total body weight and also the percent of
body weight existing as adipose tissue. Fat is the pri-
mary depot for PCB distribution. After incorporating
a term for increasing fat volume in the model, the sim-
ulations appeared as the solid line in the figure. What
initially appeared to be washout of HCB was, in fact, a
dilution effect due to the increasing fat volume. Thus,
the pharmacokinetic model proved useful in identifying
the storage ofthis highly lipid-soluble xenobiotic in fat
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tissue, an observation with possible implications for
eventual toxicity.
Physiological
Parameters that fall into the physiologic category in-
clude blood flow rate, clearance, and metabolism rates.
Figure 7 illustrates how blood flow rate, a simple but
often overlooked transport mechanism, can affect the
distribution and tissue uptake ofcirculating chemicals.
The figure shows three different compartments or tis-
sues, each having a different blood perfusion rate per
unit volume of tissue, as shown by the three values of
Q/V. If a subject is exposed to a constant level oftoxic
contaminant, eventually the blood orplasma concentra-
tion of the subject will reach a steady-state level. For
the example in Figure 7A, this concentration is arbi-
trarily set at 1.0. If a tissue is rapidly perfused, e.g.,
liver, so that the blood flow rate per unit volume of
tissue is high, then the tissue concentration rises very
rapidly, as illustrated by the upper curve in Figure 7A.
If, onthe otherhand, the blood perfusion perunittissue
volume is low, for example, adipose tissue or skin, then
the lower curve might represent that tissue's concen-
tration over time when exposed to the same blood con-
centration, and we can see a slower rise in concentra-
tion. To pursue this example further, if the exposure
were to cease at five time units, then one can see that
the more highly perfused tissue would have about four
or five times the concentration ofchemical as the more
slowly perfused tissue with the possible implication of
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a more toxic response in the former tissue. A corollary
in this example is that ifthe blood concentration begins
to decline after cessation of exposure, then the more
rapidly perfused tissue will have a rapid washout of
chemical and the more slowly perfused tissue would
washout more slowly and have a prolonged, though
lower level ofchemical, in that tissue. This example, of
course, assumes that the chemical is freely diffusible
and not bound.
A situation similar to the washout in Figure 7A is
represented in Figure 7B, which shows the concentra-
tion in three tissues with different perfusion rates after
exposure to an acute, single bolus of chemical in the
blood that eventually is cleared. The rapidly perfused
tissue achieves a high peak concentration but washes
outrapidly; the slowlyperfused tissue has amuchlower
peak concentration, but it persists for a longer time.
The question ofwhich situation would be more toxichas
no clear-cut answer. It would depend onthe mechanism
of the toxicity and on the toxic agent. For compounds
whose evokedresponseisdependent onpeaktissuecon-
centration, then the upper curve is more toxic. For
example, the lowering of blood pressure by minoxidil
(9) orthe degree ofparalysis fromtubocurrarine (9) are
determined by magnitudes of blood or tissue levels.
However, excessive peak levels could cause seizure or
death. If, on the otherhand, the chemical was cytotoxic
during certain phases of cell replication (i.e., cell-cycle
specific), a toxic response would be evoked only if a
sufficient tissue concentration were maintained long
enough to cover the sensitive cell cycle time. In such a
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FIGURE 7. Computer simulation ofthe concentration ofan administered chemical in several hypothetical compartments each with a different
ratio ofblood perfusion totissuevolume, Q/V. (A) Exposure to aconstant blood concentration; (B) exposure to adecliningbloodconcentration
after a single acute exposure.
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case, the lower curve in Figure 7B might prove to be
a more toxic time course for such a chemical. Examples
of this effect have been described in the literature for
chemotherapeutic agents (10-13), although the same
principles can apply to certain toxins.
It is important to recognize that even simple consid-
erations, like tissue blood flow, though a pharmacoki-
netic phenomena, can have implications on toxic re-
sponse to a chemical and should be taken into account.
Clearance
Clearance relates to mechanisms ofremoval ofchem-
icals from the body by such systems as the kidney via
urinary elimination, and liver and gut via biliary and
fecal elimination. Obviously, the ability to remove a
toxic chemical from the body influences the degree and
duration of toxic response. Clearance, as a physiologic
model parameter, provides a useful format in pharma-
cokinetic analysis for interspecies extrapolation. Ex-
amples exist where certain clearance values follow an
empirical correlation among several species so that pre-
dictions in man can be made for the rate of removal of
a chemical based on animal experiments using a phar-
macokinetic model (14-16). Figure 8 shows an example
of such a correlation for the kidney clearance of the
anticancerdrugcytosine arabinoside (ARA-C) as afunc-
tion ofbody weight (17). Represented in the figure are
data collected from mouse, dog, monkey, and man. The
correlation with body weight is quite good. Human
clearance values for particular environmental contam-
inants may be estimated by similar extrapolation pro-
cedures and used in pharmacokinetic models to predict
human concentrations.
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FIGURE 8. A correlation forkidney clearance ofcytosine arabinoside
versus body weight of several mammalian species. Slope of the
line is approximately 0.8. (0) Data points from left to right are
from mouse, dog, monkey, and human, respectively.
Metabolism
Another physiological parameter that is extremely
significantintheconsideration oftoxicityismetabolism.
In one case, metabolism may be responsible for the
formation of a reactive species in vivo and would con-
tribute totoxicity, whereasinanothercase, metabolism
may be the essential step in a detoxification process
either by reducing the toxic form to an innocuous form,
or by conjugating the toxic species prior to its eventual
removal from the body. Often, metabolic processes in
the body are enzymatic and follow Michaelis-Menten
kinetics. As such, the rate of reaction can be a linear
function of concentration at low doses and nonlinear at
highdoses. Theconsequencesofextrapolatinghighdose
data to low dose response predictions without account-
ingfornonlinearmechanisms hasbeendescribed earlier
in this paper with references to Figures 2 and 3.
Aside from dose extrapolation, interspecies extrap-
olation ofmetabolic data is relevant to toxicity studies,
as most predictions for human response are based on
animal data. Improper consideration of metabolic dif-
ferences among species, both qualitative and quanti-
tative, can lead to erroneous conclusions about toxicity.
Unfortunately, metabolism rates are the most con-
foundingparameters to extrapolate from species to spe-
cies. An example ofthe unpredictability ofmetabolism
rates across species is evident from previous pharma-
cokinetic analysis ofPCBs in mouse, rat, dog, and mon-
key (18). Table 1 shows the metabolism rates reported
in terms ofclearance values (mL/min) for these species
for three congeners ofPCB. The upper halfofthe table
shows that the metabolismrates increasemonotonically
with increasing size ofthe animal as one might expect.
This is true for each ofthe three congeners studied. If,
however, an intrinsic metabolic rate is calculated as
milliliters per minute per kilogram of body weight, a
differentpattern emerges. The mouse and rathave sim-
ilarintrinsicmetabolicrateconstantsforeachcongener,
whereas the money has lower rate constants, and the
dog, higherrate constants. These metabolism constants
arereflected inthehalf-livesofthePCBsintheseanimal
species, since metabolism and subsequent conjugation
are generally considered to be a prerequisite to elimi-
nation of PCBs by bile and feces. Under these circum-
stances, itwouldbedifficulttomake aprioripredictions
ofwhich species would serve as the best animal model
Table 1. Metabolic clearance of PCBs in several species.
PCB Mouse Rat Monkey Dog
Ki,m mL/min
4,4'-DCB 0.37 2.0 7.0 470
2,4,5,2',4',5'-HCB 0.01 0.045 0.67 16.0
2,3,6,2',3',6'-HCB N/A 5.0 15.0 183
Km, per kg body weight, mL/min/kg
4,4-DCB 9.7 8.0 1.4 39
2,4,5,2',4',5'-HCB 0.25 0.18 0.13 1.33
2,3,6,2',3',6'-HCB N/A 20 3.0 15.2
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ofhuman response to PCB exposure. Here again, how-
ever, a pharmacokinetic model can be very useful,
because it can incorporate a recently advanced method
known as in vitro-in vivo correlation. The method uses
in vitro systems, such as tissue homogenates, micro-
somal preparations, and even isolated, perfused organs
from each animalspecies to estimate metabolicrate con-
stants for that species (19-23). The reactions are fre-
quently enzymatic. Comparable tissues orpreparations
are often available from human subjects, for example,
from biopsy specimens. The in vitro reaction rate con-
stants determined from all species, including humans,
canbe compared, and whenconverted toaproperbasis,
can be incorporated as a metabolism parameter in the
appropriate compartment in the physiological pharma-
cokinetic model for prediction of concentrations. Such
invitro-in vivo correlation schemes, whichhave already
been reported in the literature, show great promise
towardimprovingpredictability inhumanswheninvivo
metabolic data are not otherwise available.
Thermodynamic
Thermodynamic parametersrelateprimarilytoterms
that describe purely physical interactions ofexogenous
chemical with biological tissues and fluids in the form
ofequilibrium distributions such as protein binding and
tissue partitioning. Their values determine the total
concentration of chemical in a tissue relative to blood.
In contrast to metabolism values, these parameters are
quite similar from species to species (15,16). Figure 9
helps to illustrate this point using the example of
2,4,5,2',4',5'-hexachlorobiphenyl (HCB) distribution in
several tissues ofthe rat. The fat or adipose tissue has
the highest concentration of HCB, skin is next, and
muscle tissue is the lowest. This order ofconcentration
reflects the high degree of lipid solubility of PCB, and
this thermodynamic property is remarkably similar
from species to species, as shown by a comparison of
partitioning coefficients for mouse, rat, dog, and mon-
key (18). This greatly enhances interspecies extrapo-
lation, including predictions of levels in humans. Also,
in vitro-in vivo correlations are possible for thermo-
dynamic parameters as well, for example, by cross-cor-
relating lipid content or specific binding protein levels
from tissues of different species (24-26). These ther-
modynamic parameters are easily incorporated into the
pharmacokinetic model.
Transport
Another concept to considerinrisk assessment analy-
sis is the time-dependent concentration ofa toxic agent
at the intracellular site of action. This process is rep-
resented by the biological model in Figure 2. In some
cases, thetime course ofuptake ofachemicalby atissue
is limited by blood flow rate to that tissue, as described
previously. However, in other instances, the rate of
tissue uptake may be controlled bythe rate oftransport
across cell membranes to the intracellular compart-
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FIGURE 9. The concentration-time course of 2,4,5,2',4',5'-hexa-
chlorobiphenyl in the rat for several tissues. This illustration
reflects tissue-specific partitioning of 6-CB according to a ther-
modynamic equilibrium that is predictable across several species
such as mouse, rat, dog, and monkey.
ment. The controlling factor depends on the relative
values of blood flow rate and membrane permeability
of each tissue. If the former is much smaller, then we
refer to this as "flow-limited" uptake, if the latter is
much smaller, then "membrane-limited" uptake pre-
dominates. The limiting factor can vary from tissue to
tissue or even from chemical to chemical in a given
tissue.
For membrane transport, two mechanisms are pos-
sible, one in which the transmembrane transport occurs
primarilybypassive diffusion acrossthe cellmembrane;
theother, inwhichfacilitated orcarrier-mediated trans-
port occurs across the cell membrane, whereby the dif-
fusing chemical first binds to a carrier protein on the
cell membrane surface and then the whole complex is
transported through the membrane to the intracellular
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FIGURE 10. A computer simulation showing the intracellular concentration of a chemical as a result of transport across cell membranes. (A)
A saturable transport mechanism after exposure to several blood concentrations, C,; (B) a linear, nonsaturable transport mechanism after
exposure to the same blood concentrations as in (A).
compartment. The former situation is usually a linear
process as a function ofconcentration; the latter can be
saturable and nonlinear.
Examples of each of these situations follow. Figure
10 illustrates a computer simulation ofthe intracellular
concentrations ofsome exogenous chemical underthree
different exposure conditions wheretheblood orplasma
concentration, Cp, increases by 10-fold in each case. The
model used to generate the curves in Figure 10A rep-
resent a linear mechanism for membrane transport,
such as simple diffusion proportional to Cp. The intra-
cellular concentrations are seen to rise proportionately
with the exposed dose. On the other hand, the illustra-
tions in Figure 10B depict computer simulations of a
saturable transport mechanism. In this example, the
saturation of the carrier-mechanism begins to occur at
a plasma concentration near Cp = 1.0. This happens to
be the value of the dissociation constant of the sub-
strate-carrier complex, Km= 1.0. At low doses, when
the plasma concentrations are below Cp = 1.0, the
transport appears to be linear, as intracellular concen-
trations are nearly proportional toCp as in Figure 10A.
However, at higher doses, when Cp exceeds 1.0, the
intracellular concentration is no longer proportional to
dose for the same time of exposure. Longer exposure
times will eventually allow intracellular concentrations
to rise up to the blood levels.
These examples provide further evidence of the
importance of pharmacokinetic analysis in interpreting
toxicity assays. According tothese examples, situations
could exist where knowledge of the ambient exposure
levels or even blood levels alone is not sufficient to cor-
relate with possible toxic responsebecause intracellular
concentrations maynotbeproportionaltovaryingexpo-
sure levels. Likewise, the temporal nature ofthe expo-
sure may be important in determining actual tissue
uptake at a site of action. The pharmacokinetic model
is capable ofincorporating this relevant information.
In summary, then, pharmacokinetic analysis is an
important asset, ifnot an essential ingredient in inter-
preting host response to toxic chemicals. Pharmacoki-
netic models are useful tools for describing and pre-
dicting pharmacokinetic events, especially when they
incorporate relevant anatomical and physiological
parameters similar to those described here. The model
is anexcellent didactic devicethatforcesustoformulate
ourhypothesisinanorganizedformat. Themodelallows
ustoextrapolate fromhighdosetolowdose; extrapolate
from species to species; and account for temporal var-
iations in dose. All ofthese factors are certainly impor-
tant considerations in risk assessment.
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